Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend

Reuters

Mar 13

Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend

Overview

US biopharmaceutical firm's Q4 net loss narrowed as R&D and G&A expenses declined
Company ended Q4 with $7.6 mln cash, up from $3.7 mln a year earlier

Outlook

Company preparing to advance ibezapolstat to international Phase 3 pivotal trials for CDI

Result Drivers

LOWER R&D EXPENSES - Q4 R&D expenses fell due to reduced manufacturing and consulting costs, mainly as prior year included higher trial-related expenses
LOWER G&A EXPENSES - Q4 G&A expenses decreased mainly due to lower compensation-related costs and professional fees

Company press release: ID:nPn15S9jPa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		-$0.73
Q4 Net Income		-$1.6 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $25.50, about 409% above its March 12 closing price of $5.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619199970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619199970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619199970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619199970","market":"nz","top_or_hot":-1,"title":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Acurx Pharmaceuticals Q4 net loss narrows on lower R&amp;D spend</title></head><body><p><span>Overview</span></p><ul><li><p>US biopharmaceutical firm's Q4 net loss narrowed as R&amp;D and G&amp;A expenses declined</p></li><li><p>Company ended Q4 with $7.6 mln cash, up from $3.7 mln a year earlier</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company preparing to advance ibezapolstat to international Phase 3 pivotal trials for CDI</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER R&amp;D EXPENSES - Q4 R&amp;D expenses fell due to reduced manufacturing and consulting costs, mainly as prior year included higher trial-related expenses</p></li><li><p>LOWER G&amp;A EXPENSES - Q4 G&amp;A expenses decreased mainly due to lower compensation-related costs and professional fees</p></li></ul><p>Company press release: <span>ID:nPn15S9jPa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.73</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$1.6 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $25.50, about 409% above its March 12 closing price of $5.01</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcurx Pharmaceuticals Q4 net loss narrows on lower R&D spend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-13 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Acurx Pharmaceuticals Q4 net loss narrows on lower R&amp;D spend</title></head><body><p><span>Overview</span></p><ul><li><p>US biopharmaceutical firm's Q4 net loss narrowed as R&amp;D and G&amp;A expenses declined</p></li><li><p>Company ended Q4 with $7.6 mln cash, up from $3.7 mln a year earlier</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company preparing to advance ibezapolstat to international Phase 3 pivotal trials for CDI</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER R&amp;D EXPENSES - Q4 R&amp;D expenses fell due to reduced manufacturing and consulting costs, mainly as prior year included higher trial-related expenses</p></li><li><p>LOWER G&amp;A EXPENSES - Q4 G&amp;A expenses decreased mainly due to lower compensation-related costs and professional fees</p></li></ul><p>Company press release: <span>ID:nPn15S9jPa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.73</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$1.6 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $25.50, about 409% above its March 12 closing price of $5.01</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL1N4010F2:1","article_id":"2619199970","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619199970","pubTimestamp":1773400205,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewUS biopharmaceutical firm's Q4 net loss narrowed as R&D and G&A expenses declinedCompany ended Q4 with $7.6 mln cash, up from $3.7 m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4539":"次新股","ACXP":"Acurx Pharmaceuticals, LLC*","BK4139":"生物科技"},"translate_title":"Acurx Pharmaceuticals第四季度净亏损因研发支出减少而收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACXP":0.9},"content_text":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewUS biopharmaceutical firm's Q4 net loss narrowed as R&D and G&A expenses declinedCompany ended Q4 with $7.6 mln cash, up from $3.7 mln a year earlierOutlookCompany preparing to advance ibezapolstat to international Phase 3 pivotal trials for CDIResult DriversLOWER R&D EXPENSES - Q4 R&D expenses fell due to reduced manufacturing and consulting costs, mainly as prior year included higher trial-related expensesLOWER G&A EXPENSES - Q4 G&A expenses decreased mainly due to lower compensation-related costs and professional feesCompany press release: ID:nPn15S9jPaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPS-$0.73Q4 Net Income-$1.6 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $25.50, about 409% above its March 12 closing price of $5.01For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}